MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to put mantle cell lymphoma into deep remission
Disease control OngoingThis phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThis study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control OngoingThis early-stage trial tests two new drug combinations for people with untreated mantle cell lymphoma, a rare blood cancer. One group gets acalabrutinib plus standard chemo and an antibody; the other gets acalabrutinib plus a targeted pill and the same antibody. The main goal is …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New pill shows promise for tough blood cancer
Disease control OngoingThis phase 2 trial tests an oral drug called rocbrutinib in 62 people with mantle cell lymphoma that has come back or not responded to other treatments. Participants take the drug once daily until their disease worsens or side effects become too severe. The main goal is to see ho…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC